Proteases and protease-activated receptors (PARs) are major mediators involved in irritable bowel syndrome (IBS). Our objectives were to decipher the expression and functionality (calcium signaling) of PARs in human dorsal root ganglia (DRG) neurons and to define mechanisms involved in human sensory neuron signaling by IBS patient mediators. Human thoracic DRG were obtained from the national disease resource interchange. Expression of PAR 1 , PAR 2 , and PAR 4 was assessed by immunohistochemistry and quantitative reverse transcription PCR (RT-qPCR) in whole DRG or in primary cultures of isolated neurons. Calcium signaling in response to PAR agonist peptides (PAR-AP), their inactive peptides (PAR-IP), thrombin (10 U/mL), supernatants from colonic biopsies of patients with IBS, or healthy controls, with or without PAR 1 or PAR 4 antagonist were studied in cultured human DRG neurons. PAR 1 , PAR 2 , and PAR 4 were all expressed in human DRG, respectively, in 20%, 40%, and 40% of the sensory neurons. PAR 1 -AP increased intracellular calcium concentration in a dose-dependent manner. This increase was inhibited by PAR 1 antagonism. By contrast, PAR 2 -AP, PAR 4 -AP, and PAR-IP did not cause calcium mobilization. PAR 1 -AP-induced calcium flux was significantly reduced by preincubation with PAR 4 -AP, but not with PAR 2 -AP. Thrombin increased calcium flux, which was inhibited by a PAR 1 antagonist and increased by a PAR 4 antagonist. Supernatants from colonic biopsies of patients with IBS induced calcium flux in human sensory neurons compared with healthy controls, and this induction was reversed by a PAR 1 antagonist. Taken together, our results highlight that PAR 1 antagonism should be investigated as a new therapeutic target for IBS symptoms.
Introduction
Irritable bowel syndrome (IBS) affects 11% to 20% of the Western population with a higher prevalence in women. 14, 31 Irritable bowel syndrome associates abdominal pain, diarrhea (IBS-D), constipation (IBS-C), or both (IBS-A, for alternate). 30 Although IBS is a functional gastrointestinal disorder, not associated with gross structural or biochemical abnormalities, 23 several recent studies indicate the presence of meaningful microorganic changes. 7 One of the emerging ideas to explain the visceral pain associated with IBS is that sensory neurons innervating the colon are hyperexcitable in these patients. 10, 11, 13 However, because of the difficulties associated with human sensory neuron cultures, it has been difficult to evaluate the relevance of identified mediators in the context of human pathology.
Among the molecular targets explored to decipher neuronal hyperexcitability in IBS, several studies showed that proteases released by colonic biopsies of patients with IBS were able to activate mouse and rat intestinal neurons in vitro and to induce somatic and visceral hypersensitivity in vivo. 9, 13, 17, 38, 47 Proteases are known to signal to mouse or rat sensory neurons through the activation of protease-activated receptors (PARs), 19, 46, 53, 55 a family of G protein-coupled receptors that includes 4 members: PAR 1 , PAR 2 , PAR 3 , and PAR 4 . 40 Only PAR 1 , PAR 2 , and PAR 4 seem to be able to signal through calcium mobilization and to exert a role in nociception and pain (PAR 3 has been considered more as a cofactor for other PAR activation 35 so far). PAR 1, 2, and 4 are activated by the proteolytic cleavage of their N-terminal domain, which reveals a tethered ligand that binds and activates the receptors. The role of PARs in visceral inflammation and pain has been well studied in animal models. 49, 50 Both PAR 1 and PAR 2 agonists induce calcium mobilization in rodent sensory neurons. 17, 21 PAR 2 agonists induce pain in somatic and visceral models, 51, 53 whereas PAR 1 and PAR 4 agonists attenuate nociception and pain symptoms in rodents. [4] [5] [6] 32 In mouse sensory neurons, the calcium mobilization induced by supernatants from colonic biopsies of patients with IBS is dependent on supernatant's proteolytic activity and on PAR 2 expression in mouse primary afferents. 17 By contrast, PAR 4 activation inhibits PAR 2 -induced calcium mobilization and intrinsic excitability of colonic dorsal root ganglia (DRG) neurons, as well as overall pain. 5, 6, 28 However, in the context of human nociception and pain, the effects of PAR agonists and PAR signaling mechanisms are largely unknown.
Proteases show different specificity for the different PARs. 52 For instance, thrombin can activate PAR 1 , PAR 3 , PAR 4 , and to a lower extent, PAR 2 , trypsin can activate PAR 2 , PAR 3 , PAR 4 , and at high concentrations, PAR 1 . 25, 33, 42 In the context of IBS, tryptase and trypsin-3 are upregulated and are considered as possible endogenous agonists for PARs. 9, 43 Our study aimed at deciphering PAR signaling in human sensory neurons, determining whether proteases and PARs could play a role in human sensory neuron biology and nociceptive mechanisms. Furthermore, we investigated human sensory neuron responses to IBS mediators in cultured human DRG neurons. Although not only neurons projecting from the digestive tract are present in our cultures, this study could give insights in the response of human primary afferents to mediators present in IBS patient tissues.
Methods

Chemicals
Each agonist and inactive peptides of PARs, respectively, PAR-AP and PAR-IP, where purchased from Genscript (France): PAR 1 -AP (TFFLR), PAR 2 -AP (SLIGKV), PAR 4 -AP (GYPGQV), PAR 1 -IP (RLLFT), PAR 2 -AP (LRGILS), and PAR 4 -AP (YAPGQV). Thrombin, PAR 1 antagonist (SCH79797), PAR 2 antagonist (GB83), and PAR 4 antagonist (ML354) were obtained from Tocris (Denver, CO).
Patient biopsies and supernatant collection
Colon biopsy samples from 24 patients with IBS (8 IBS-D, 8 IBS-C, and 8 IBS-A) and 5 healthy controls (HCs) undergoing colorectal cancer screening were collected during colonoscopy at the Department of Medical and Surgical Sciences of the University of Bologna, Italy (Supplementary Table 1 , available online at http:// links.lww.com/PAIN/A553). Rome III criteria were used for the diagnosis of patients with IBS. Additional exclusion criteria were major abdominal surgery, celiac disease, asthma, allergic disorders, anti-inflammatory treatments, and organic syndrome. Symptoms as bloating, pain, and bowel habit changes in the last 12 months were also excluded from control group.
Supernatants from colonic biopsies were obtained after a previously validated and published method, 8 with few modifications. Briefly, after removal, biopsies were immersed in plastic tubes containing 1 mL of Hepes-Krebs solution. After weighing the biopsies, supernatant volume was adjusted to incubate 15 mg of biopsies in 1 mL of buffer. Incubation was performed in oxygenation at 37˚C for 25 minutes. Samples were centrifuged at 200g for 10 minutes and supernatant collected and stored at 220˚C until the assay.
Human dorsal root ganglia neurons isolation
Experiments were conducted under the Institutional Review Board numbers IRB00003888, FWA00005831. Human DRG (thoracic position 11 and 12) were collected in Dulbecco's Modified Eagle's medium by the National Disease Resource Interchange (NDRI). Twenty DRG were obtained from 10 postmortem donors (21-60 years old, 10 hours maximum postmortem) with the following exclusion criteria: chemotherapy, drug abuse, infectious disease, neurodegenerative diseases, and opioid medications. None of the donors had a reported history of colitis or inflammatory bowel disease, but no information was provided about possible IBS. Dorsal root ganglia were cut into small pieces, rinsed in Hank's balanced salt solution (HBSS; Thermo Fisher, Villebon-sur-Yvette, France) and digested in L-cystein (pH 7.4; Sigma Aldrich, Saint Quentin Fallavier, France), papain (27 mg/mL; Sigma Aldrich) for 20 minutes at 37˚C, and rinsed 2 minutes in Leibovitz L15 Medium (Thermo Fisher Scientific, Waltham, MA) containing 10% of FBS. A second enzymatic dissociation was performed in 4-mg/mL dispase II (Sigma Aldrich) and 1-mg/mL collagenase (collagenase type IV; Serlabo Technologies, Entaigues-sur-laSorgue, France) for 15 minutes at 37˚C, followed by mechanical dissociation. This step was repeated until complete dissociation of the DRG up to 4 times. Finally, neurons were plated in 8-wells Nunc Lab-Tek II CC2 chamber slide system (Thermo Fisher Scientific) and cultured for 7 days in complete Neurobasal-A medium (Thermo Fisher Scientific) containing penicillin (100 mg/mL), streptomycin (100 mg/mL), B27 (1X; Thermo Fisher Scientific), L-glutamine (1X; Thermo Fisher Scientific), and inhibitors of mitosis (Cytosine-Barabinofuranoside 1.5 mM, F-Uridine 10 mM, Uridine, 10 mM, Sigma Aldrich). Cytosine-B-arabinofuranoside was removed after 3 days of culture and the medium was changed every 2 days.
For quantitative reverse transcription PCR (RT-qPCR) and single-cell PCR studies, human thoracolumbar DRG (T9-L1) were acquired from 5 (3 females, 2 males) human adult organ donors (22.2 6 2.08 years of age) during the removal of vital organs for transplantation. The harvested intact DRG were kept for RTqPCR mRNA expression studies, whereas additional DRG were dissociated to allow individual DRG neurons to be isolated and studied with single-cell reverse transcription PCR.
Calcium imaging of human sensory neurons
After washing with HBSS, cultured neurons were incubated for 1 hour (30 minutes at 37˚C followed by 30 minutes at room temperature) in solution containing fluo-4 acetoxymethyl (AM) 1 mM (Thermo Fisher Scientific) reconstituted in 0.01% pluronic F-127 and 0.7% DMSO (Sigma Aldrich). The fluorescence was measured at 460-to 490-nm excitation and 515-nm emission in each well. Neurons were imaged using an inverted microscope (10x-objective; Zeiss, Marly-le-roi, France) and a CCD camera (Zeiss). Acquisition parameters were kept constant within each experiment. A kinetic of 80 recordings (one per second) was performed. From 0-to 5-second basal fluorescence was determined, from 6 to 60 seconds, neurons were exposed to the different molecules studied and finally to a KCl solution (50 mM), to discriminate neurons from glial cells. Neurons were identified by Image J software, and variations in the fluorescence intensity of each neuron were measured. Results were expressed as DF/F, representing the fluorescence intensity ratio between the highest measure during the 6-to 60-second period and baseline measure.
In a first set of experiments, neurons were treated with individual PAR agonist peptides: PAR 1 -AP (1, 10, 50, or 100 mM), PAR 2 -AP (100 mM), PAR 4 -AP (100 mM), or neurons were preincubated for 5 minutes with PAR 2 -AP (100 mM) or PAR 4 -AP (100 mM), before being exposed to PAR 1 -AP (100 mM). For these experiments, the inactive peptides (PAR-IP, 100 mM) and vehicle (HBSS) were used as control. In a second set of experiments, neurons were preincubated for 5 minutes with antagonist of PAR 1 (SCH79797, 10 mM) or its vehicle (HBSS, 0.01% DMSO) and treated with PAR 1 -AP (100 mM). In a third set of experiments, neurons were pretreated 5 minutes with the PAR 1 antagonist (SCH79797, 10 mM), the PAR 4 antagonist (ML354, 10 mM), or vehicle (HBSS, 0.01% DMSO) and were then treated with thrombin (10 U/mL). In a last set of experiments, neurons were pretreated 5 minutes with the PAR 1 antagonist (SCH79797, 10 mM) or vehicle, before being exposed to supernatants from colonic biopsies of patients with IBS-D, IBS-C, IBS-A or HCs.
Immunofluorescence in human dorsal root ganglia
Experiments were conducted under the Institutional Review Board numbers IRB00003888, and FWA00005831. Three human DRG T11 and 3 DRG T12 (thoracic position 11 and 12) were cryoprotected in Tissue-Tek optimum cutting temperature compound (Sakura Finetek, Villeneuve d'Ascq, France) after their collection by the NDRI. Cryoprotected DRG were cut into 35-mm sections in a cryostat (Leica CM1950; Nanterre, France) and mounted on Superfrost slides (Thermo Fisher Scientific, Villebonne-sur-Yvette, France). Cultured DRG neurons were fixed with paraformaldehyde 4% during 20 minutes. Both slides and cultures were washed in phosphatebuffered saline (PBS), 0.5% Triton X-100, and 1% bovine serum albumin solution (BSA; Sigma Aldrich) and were incubated overnight at 4˚C with primary antibodies diluted at 1:100 for tissues and 1:500 for cultures and directed against PGP9.5, PAR 1 , PAR 4 (respectively, AB86808, AB111976, AB70400, Abcam, Cambridge, United Kingdom), and PAR 2 (LSB2321; LifeSpan, Seattle, WA). After washing in PBS, slices or cultures were incubated with the appropriate secondary antibody conjugated to Alexa Fluor 488 or Alexa Fluor 555; they were washed and mounted with ProLong Gold reagent containing 40,6-diamidino-2-phenylindole (DAPI; Molecular Probes, Eugene, OR). Controls for the specificity of the antibodies include incubation in the absence of secondary antibody, incubation in the presence of immunizing peptides, and the use of PAR-deficient tissues or cells (not shown). Images were acquired using Zeiss LSM-710 confocal microscopes (Carl Zeiss MicroImaging, Jena, Germany) with 103 objective in the inverted configuration. 20 Quantification of labelling was determined using Image J software.
Quantitative reverse transcription PCR
RNA was extracted from either whole human DRG or single human DRG neurons using RNA-isolation kits (PureLink and Cells-to-CT; Ambion, Huntingdon, United Kingdom). Quantitative reverse transcription PCR was performed using human-specific Taqman primers for PAR 1 , PAR 2 , PAR 4 , and GAPDH (Hs00169258_m1, Hs00608346_m1, Hs00765740_m1, Hs01006385_g1, Hs99999905_m1). The comparative cycle threshold method was used to quantify the abundance of target transcripts to reference genes.
Single-cell PCR
Twenty-six single dissociated DRG neurons were picked using a micromanipulator at 340 magnification. Cells were under a continuous slow flow of sterile and RNA/DNAse free PBS to reduce contamination. After a cell was picked, the glass capillary was broken into a tube containing 10 mL of Lysis buffer and DNAse (TaqMan Gene Expression Cells-to-CT Kit; Ambion). The whole content was used for cDNA synthesis (SuperScript VILO cDNA Synthesis Kit; Thermo Fisher) and PAR 1 , PAR 2 , PAR 4 expression was measured using Taqman RT-qPCR for 50 cycles. For every coverslip, a bath control was taken and analyzed together with samples. TUBB3 (Hs00964962_g1) expression served as positive control. One cell was excluded because no TUBB3 expression was present. Twenty-six cells were used to calculate frequency of presence of PAR 1 , PAR 2 , and PAR 4 .
Statistical analysis
Data are presented as mean 6 SEM. Analyses were performed using GraphPad Prism 5.0 software (GraphPad, San Diego, CA). Comparisons between groups were performed by Mann-Whitney test or Wilcoxon matched pairs test. Multiple comparisons within groups were performed by Kruskal-Wallis test, followed by Dunn's posttest. Statistical significance was accepted at P , 0.05.
Study approval
The collection of biopsies from colonic patients was approved by the local Ethic Committee 
Results
Protease-activated receptor expression in human dorsal root ganglia neurons
In whole human DRG, PAR mRNA expression was assessed by RT-qPCR analysis. The relative mRNA abundance of PAR 2 was the highest followed by PAR 4 and PAR 1 (Fig. 1A) . Then, to determine whether PARs were expressed in neurons at the protein level, the percentage of neurons, identified by Pgp9.5 immunostaining and expressing each PAR, was studied (Fig.  1B) . PAR 1 , PAR 2 , and PAR 4 were, respectively, expressed in 20%, 40%, and 40% of neurons (Fig. 1C) . The percentage of PAR-positive neurons was expressed in function of the diameter of neurons. PAR 1 was preferentially expressed in 30-to 50-mM diameter neurons, PAR 2 in neurons with a diameter ,30 mM, and PAR 4 in 30-to 50-mM diameter neurons (Fig. 1D) .
Protease-activated receptor expression was then assessed in cultured human DRG neurons. Cultures were 90% pure for Pgp9.5 neuronal marker staining (Supplementary Figure 1 , available online at http://links.lww.com/PAIN/A553). Single-cell polymerase chain reaction experiments showed that PAR 1 , PAR 2 , and PAR 4 mRNA were, respectively, expressed in 20%, 25%, and 17% of neurons ( Fig. 2A left panel) . We found that 75% of PAR 1 expressing neurons also expressed PAR 2 , 100% of the PAR 4 expressing neurons also expressed PAR 2 , whereas 25% of the PAR 1 expressing neurons also expressed PAR 4 ( Fig. 2A right  panel) . PAR 1 , PAR 2 , and PAR 4 were, respectively, expressed at the protein level in 35%, 36%, and 27% of neurons (Figs. 2B and  C) . These results demonstrate that human DRG neurons in culture continue to express PAR 1 , PAR 2 , and PAR 4 , and no major or significant difference was observed between the level of expression of PARs in whole DRGs and in cultured DRGs. increase in [Ca21]i that was maximal after 20 seconds and declined to baseline afterwards, compared with PAR 2 -AP and PAR 4 -AP (Fig. 3A) . This activation was characterized by an increased percentage of responding neurons (Fig. 3B) and increased amplitude (DF/F) of response (Fig. 3C) , compared with its inactive peptide (PAR 1 -IP, 100-mM). PAR 1 -AP-induced calcium mobilization was dose dependent (Fig. 3D) and abolished by a PAR 1 antagonist (SCH79797, 10-mM) (Fig. 3D) . Agonists and inactive peptides of PAR 2 and PAR 4 (all at 100-mM) had no significant effect on calcium signaling in human-cultured DRG (Figs. 3A-C) .
As PAR 2 and PAR 4 agonist peptides did not induce calcium mobilization, we tested their potential inhibitory role on PAR 1 -AP-induced calcium flux. Human DRG were pretreated with PAR 2 -AP or PAR 4 -AP and, 5 minutes later, PAR 1 -AP was added (all agonists at 100 mM). The transient increase in [Ca21]i induced by PAR 1 -AP was decreased by PAR 4 -AP but not by PAR 2 -AP pretreatment (Fig. 3E) . Both the percentage of responding neurons and the amplitude of response induced by a PAR 1 agonist were significantly reduced by PAR 4 -AP, but not by PAR 2 -AP pretreatment (Figs. 3F and G) . 1, 10, 50 , and 100 mM, black bar) pretreated or not with a PAR 1 antagonist (SCH79797, 10 mM). n 5 4 to 5 independent experiments of 3 wells per condition and 36 to 62 neurons per well. (E) Representative trace of calcium flux experiment obtained in one well of human sensory neurons culture exposed to PAR 1 -AP (100 mM) and preincubated with PAR 2 -AP or PAR 4 -AP (100 mM each). Percentage of responding neurons (F) and amplitude of intracellular calcium mobilization (DF/F; G) in human sensory neurons exposed to PAR 1 -AP (100 mM, all bars) and pretreated with PAR 2 -IP or PAR 4 -IP (100 mM, white bar), PAR 2 -AP (100 mM, gray bar) or PAR 4 -AP (100 mM, black bar). n 5 3 to 4 independent experiments of 3 wells per condition and 30 to 58 neurons per well. Statistical analysis was performed using Kruskal-Wallis analysis of variance and subsequent Dunn's post hoc test. *P , 0.05, **P , 0.01, ***P , 0.001, significantly different from the corresponding inactive peptide groups; £££P , 0.001, significantly different from PAR 1 -AP (100 mM).
Thrombin signals to human dorsal root ganglia neurons
Considering the calcium mobilization responses of human sensory DRG neurons to PAR 1 and PAR 4 peptidic agonists, we investigated the effects of thrombin (10 U/mL), a known endogenous activator of both PAR 1 and PAR 4 . The average amplitude of thrombin-induced calcium response in human DRG neurons was significantly increased compared with vehicle (Fig.  4A) . Pretreatment with a PAR 1 antagonist (SCH79797, 10 mM) significantly reduced the effects of thrombin on the percentage of responding neurons. Pretreatment with a PAR 4 antagonist (ML354, 10 mM) had no effect on this parameter (Fig. 4B) . Considering only neurons that responded to thrombin by mobilizing calcium (23% or all neurons), the amplitude of their response to thrombin was significantly increased in the presence of PAR 4 antagonist but was not modified by a PAR 1 antagonist (Fig. 4C) . These results demonstrated that, in human DRG neurons, thrombin activates both PAR 1 and PAR 4 , exerting opposite effects in terms of calcium mobilization.
Irritable bowel syndrome patient mediators mobilize calcium in human dorsal root ganglia neurons through a PAR 1 -dependent mechanism
Irritable bowel syndrome supernatants, but not supernatants from HC, evoked a transient increase in [Ca21] i that was maximal after 30 seconds and declined to baseline afterwards (Fig. 5A) . (Fig.  5D) . The antagonist significantly reduced both the percentage of responding neurons to IBS supernatants (all IBS subgroups together) and the amplitude of their response (Figs. 5E and F) .
Discussion
Since their discovery in rodent neurons, 46, 53 PARs have been considered as new important therapeutic targets for the treatment of pain. A number of in vivo and in vitro studies have confirmed this potential role for PARs, particularly in the context of visceral pain and hypersensitivity. 19, 49, 51, 52 However, the relevance of considering PAR signaling as an important pathway for human pain has not been thoughtfully addressed thus far. Indeed, only one study performed in human subjects refers to a possible role for PAR 2 in pruritus, 45 but no study has investigated the expression and functionality of PARs in human DRG neurons. Here, we provide evidences that PAR 1 , PAR 2 , and PAR 4 are all expressed in human sensory neurons. Furthermore, we showed that, in culture, the expression of PARs is generally conserved and that the culture conditions we have defined for human DRG neurons can be used to investigate the functionality of human sensory neurons. Although our results provide new insights on human primary afferent signaling, the link to activation of pain pathways would clearly require further experiments.
Previous studies performed in rodent primary afferents have demonstrated the expression of the 3 functional PARs: PAR 1 , PAR 2 , and PAR 4 . 21, 46 We confirmed here that those 3 receptors are also expressed in human primary afferent neurons both in cell bodies of whole DRG neurons and in cultures. In rodent sensory neurons, both PAR 1 and PAR 2 agonists induced calcium mobilization. [15] [16] [17] 21 By contrast, PAR 4 agonists did not mobilize calcium but decreased pronociceptive mediator-induced Figure 5 . Effects of supernatants from colonic biopsies of patients with IBS or healthy controls on calcium mobilization in human DRG neurons. (A) Representative trace of calcium flux experiment obtained in one well of human sensory neuron culture exposed to supernatant of diarrhea-predominant patient with IBS (hexagon) or to healthy control (HC, circle). Amplitude of intracellular calcium mobilization (DF/F; B) in human sensory neurons and percentage of responding neurons (C) exposed to supernatants from colonic biopsies of patients with IBS: constipation-predominant (-C, triangle), diarrhea-predominant (-D, hexagon), alternate (-A, square), or to supernatants from colonic biopsies of healthy control (HC, circle). (D) Representative trace of calcium flux experiment obtained in one well of human sensory neurons culture exposed to supernatant of alternate-predominant patient with IBS (square) and pretreated with PAR 1 antagonist (SCH79797, 10 mM, gray square) or its vehicle (white square). Amplitude of intracellular calcium mobilization (DF/F; E) in human sensory neurons and percentage of responding neurons (F) exposed to supernatants from colonic biopsies of patients with IBS: constipation-predominant (-C, triangle), diarrhea-predominant (-D, hexagon) or alternate (-A, square) and pretreated with PAR 1 antagonist (SCH79797, 10 mM), or its vehicle. Data are represented as scattered dot plot with line at mean. Each symbol represents one patient. n 5 6 independent experiments of 3 wells per condition and 42 to 53 neurons per well. Statistical analysis was performed using Mann-Whitney test (B and C) or Wilcoxon matched pairs test (E and F). *P , 0.05, **P , 0.01, significantly different from HC (B and C) or from IBS group (E and F). DRG, dorsal root ganglia; HC, healthy control; IBS, irritable bowel syndrome. calcium signaling. 6, 28 In human sensory neurons, we demonstrated that only PAR 1 agonist induced calcium mobilization. Like in rodents, in human DRG neurons, PAR 4 was not able to mobilize calcium but decreased calcium mobilization induced by other agonists. Taken together, our results clearly demonstrated that both PAR 1 and PAR 4 were present and functional in human primary afferents, where they exerted opposing effects. The PAR peptide agonists used in this study have been well characterized for their selectivity. 26, 27 The doses that were used for these peptide agonists in this study are considered to be highly selective for their targeted receptors in cell culture assays. Therefore, we can reasonably think that the results obtained are truly representative of PAR selective activation. Indeed, this was confirmed for PAR 1 activation by incubation in the presence of the PAR 1 antagonist. At the concentrations used, both SCH79797 and ML354 antagonists were considered selective for inhibition of PAR 1 and PAR 4 , respectively, compared with the inhibition of other PARs. 1, 57 However, PAR 1 -independent effects have also been described for the SCH79797 compound, 22 and one cannot rule out that the effects of this antagonist alone cannot be due to MAPK inhibition as it has been shown in cell lines at similar concentrations. 22 The PAR 4 antagonist ML354 is potent only at micromolar ranges, showing a reasonable selectivity for PAR 4 , but one cannot rule out at this concentration off-target binding for this antagonist. 57 Although DRG cultures were 90% pure for neurons, some glial cells or other supporting cells might still be present in our culture conditions. Protease-activated receptors are known to be expressed and functional in glial cells and, to some extent, glial PAR activation might account for some of the calcium responses observed in our cultures.
Translating cellular signaling of sensory neurons into nociceptive response in vivo is complex, and the study of calcium signaling in primary afferents cannot fully reflect pain pathway activation. We found no correlation between pain severity scores and pain frequency scores with the percentage of responding neurons or with the amplitude of the response to IBS tissue supernatants. This could be due to the low number of samples we included in this study considering the precious nature of human DRG neuron cultures. Indeed, other animal studies suggest that calcium signals in sensory neurons are often associated with pronociceptive signals. Calcium mobilization and increasing excitability of neurons reflected the sensitization of neurons associated with visceral hypersensitivity. 12 However, in rodents, although PAR 1 agonists mobilized calcium in primary afferents, 21 they also increased nociceptive threshold and reduced inflammatory hyperalgesia. 4, 32 In this study, we showed that PAR 1 -specific activation mobilized calcium in human sensory neurons. The pronociceptive nature of this PAR 1 signal is supported by our subsequent observations demonstrating the involvement of PAR 1 activation in IBS patient biopsy supernatants-induced activation of human sensory neurons. Interestingly, in human submucosal and myenteric plexi, PAR 1 -AP (TFLLR), thrombin, or supernatants of colonic biopsies from patients with IBS were also able to induce spike discharges and calcium signaling. This reflected enteric neuronal excitability. 29, 34 This suggests that, in humans, PAR 1 might be functional both in submucosal and myenteric neurons, as well as in primary afferents (per our results). In the context of IBS, this means that PAR 1 could contribute, as our results suggested, to hyperexcitability of extrinsic sensory neurons leading to visceral hypersensitivity symptoms but could also contribute to motor and secretory dysfunctions controlled by intrinsic enteric neurons. However, one has to be careful establishing a link between primary afferent response and activation of pain pathways, as in rodents, PAR 1 can be activated in primary afferents but was shown to be analgesic. Therefore, the pronociceptive effects of PAR 1 agonists remain to be demonstrated in humans. Our study paves the way for studying in human clinical trials the potential that PAR 1 antagonists already developed for use in human could have at reducing pain and hyperalgesia.
In agreement with the results previously generated in mouse primary afferents, 6, 28 we observed in human neurons as well, that PAR 4 -AP did not mobilize calcium, but significantly reduced calcium mobilization of stimulated sensory neurons. Here, we demonstrated for the first time an inhibitory effect for PAR 4 activation on human sensory pathways, suggesting that, like in rodents, 5, 6 PAR 4 activation could contribute at reducing pain and hypersensitivity. Taken together, our results highlight opposite effects for PAR 1 and PAR 4 activation in human primary sensory afferents. Considering that both receptors are activated by thrombin, although at different concentrations, it was important to investigate the overall effect of thrombin on human primary neuron calcium signaling. Thrombin is attracted to PAR 1 by a Hirudin-like site located at the N-terminal end of the receptor. 56 Thrombin binding facilitates the cleavage of PAR 1 , which thus does not require high concentrations of thrombin for its activation (0.1 to 1 U/mL). By contrast, PAR 4 has no hirudin-like site and higher concentrations of thrombin are requested to activate PAR 4 (10 U/mL). 36 We deliberately used a concentration of thrombin that would activate both PAR 1 and PAR 4 and observed that thrombin induced a PAR 1 -dependent calcium mobilization in human primary afferents (Figs. 4A and B) . We also observed that the amplitude of the thrombin response in human sensory neurons was reduced by concomitant PAR 4 activation. Indeed, PAR 4 blockade enhanced the amplitude of thrombin-induced calcium response (Fig. 4C) . In keeping with these functional results, our single-cell polymerase chain reaction data show that a population of human DRG neurons expressing PAR 1 also expresses PAR 4 . Interestingly, PAR 4 was strongly expressed in human DRG neurons. The magnitude of PAR 4 effect on PAR 1 -or thrombin-induced calcium signals in primary afferents was not as strong as it could have been expected considering the strong PAR 4 expression. In primary afferents, PAR 4 might have other function than counteracting the PAR 1 -induced signals.
In contrast to studies reporting calcium mobilization in rodent sensory neurons after stimulation with PAR 2 -APs, or in other human cell lines, 37, 54 we observed that human sensory neurons did not mobilize calcium after exposure to PAR 2 -APs. Interestingly, PAR 2 expression in human sensory DRG neurons was clearly demonstrated both at the mRNA and protein levels ( Figs.  1 and 2 ). This result was quite surprising because numerous studies have demonstrated that human cells expressing PAR 2 mobilize calcium after exposure to PAR 2 tethered ligand synthetic peptide. 39 The lack of calcium mobilization in human sensory neurons exposed to PAR 2 synthetic agonist does not mean that the receptor is silent or nonfunctional. Indeed, other signaling pathways that have been previously described for PAR 2 , such as pERK or cAMP signaling, might be implicated in human sensory neurons. Such pathways would have to be investigated in future studies. Furthermore, in human submucosal neurons, PAR 2 -AP induces very weak calcium mobilization, 34 whereas PAR 2 has been shown to be functional and potently activated by the trypsin-3 protease in the same neurons. 43 This suggests that, depending on the type of agonists that are tested (synthetic peptides or proteases), the cell response might be diverse and more or less potent. Similar findings have been reported for PAR pharmacology in a number of cells and tissues.
One crucial step in studying the relevance of PARs as therapeutic targets is the definition of protease profile and activities associated with pathological states. Indeed, the opposite roles for PAR 1 and PAR 4 we have defined here in human primary afferent signaling suggest that, depending on the proteases present and their concentration, pronociceptive or antinociceptive signals could be prominent. Thrombin can activate both PAR 1 and PAR 4 , but as mentioned above, at different concentrations. Therefore, the concentration of active thrombin detected in colonic tissues from patients with IBS could give an important indication on the activation status of PARs and the overall nociceptive signals. Cathepsin G activates PAR 4 44 and disarms PAR 1 . 41 Here again, the presence of cathepsin G in tissues could modify nociceptive status and accordingly participate to pain relief. Thus, it is clear that protease profiling will be an important step towards our comprehension of nociceptive signaling to primary afferents. However, the results presented here clearly defined that PAR 1 activation on sensory neurons is involved in sensory response to mediators associated with IBS in humans, although the proteases responsible for PAR 1 would still have to be confirmed in human primary afferents.
One major limitation of this study, however, is that even if we have harvested thoracic DRGs containing neurons projecting from the colon, not all neurons present in the culture dishes are colonic projections. We cannot define whether colonic projections are responding to supernatants of patients with IBS, or even whether colonic projections are indeed expressing the different PARs. In animal studies, retrograde labeling of projecting neurons is used to identify the origin of the neurons, but this is hardly applicable to human studies.
In conclusion, this study describes in human sensory neurons, the expression of PARs and their ability to generate calcium signaling. The results highlight the functionality of PAR 1 as an activator of calcium-dependent signaling and PAR 4 as an inhibitor of such signaling. Most importantly, mediators from IBS patient tissues signal to human primary afferent in a PAR 1 -dependent mechanism, illustrating the potential of PAR 1 antagonism as a new therapeutic option to treat symptoms associated with IBS.
